Alectinib, an oral, highly selective, second‐generation tyrosine kinase inhibitor (TKI), has dramatic efficacy in patients with anaplastic lymphoma kinase (ALK) rearrangement non‐small‐cell lung cancer (NSCLC).1 The gene discussed is ALK; the disease is non-small cell lung carcinoma.